Randomized clinical trials are considered the gold standard for estimating causal effects. Nevertheless, in studies that are aimed at examining adverse effects of interventions, such trials are often impractical because of ethical and financial considerations. In observational studies, matching on the generalized propensity scores was proposed as a possible solution to estimate the treatment effects of multiple interventions. However, the derivation of point and interval estimates for these matching procedures can become complex with non-continuous or censored outcomes. We propose a novel Approximate Bayesian Bootstrap algorithm that result in statistically valid point and interval estimates of the treatment effects with categorical outcomes. The procedure relies on the estimated generalized propensity scores and multiply imputes the unobserved potential outcomes for each unit. In addition, we describe a corresponding interpretable sensitivity analysis to examine the unconfoundedness assumption. We apply this approach to examines the cardiovascular safety of common, real-world anti-diabetic treatment regimens for Type 2 diabetes mellitus in a large observational database.
cardiovascular outcomes, such as myocardial infarction, stroke, and heart failure [3] . Investigation of the potential beneficial or harmful effects of new glucose-lowering medications on the incidence of major cardiovascular events via prospective, randomized controlled trials has been mandated by the FDA as part of their drug approval process starting in 2008 [4] . However, comparable trials for older anti-diabetic medications are not available, and insights into cardiovascular outcomes from real-world observational data are limited for both new and older antihyperglycemic medications.
Metformin has been recommended as a first-line agent in type 2 diabetes because of its low cost, high glucose-lowering efficacy, and low risk of hypoglycemia [5] . There are several classes of antihyperglycemic therapies with distinct mechanisms of action recommended as second-line treatments, generally used in combination with metformin [6] . Sulfonylureas, the oldest oral antidiabetic agents, result in effective glucose-lowering but are associated with weight gain and an increased risk of hypoglycemia [7] . Pioglitazone, a member of the thiazolidinedione (TZD) drug class, may offer cardiovascular benefits [8, 9, 10, 11] , although it is recommended that pioglitazone should be avoided in patients with or at risk for heart failure because of its potential to cause fluid retention [12] . For the more recently introduced dipeptidyl peptidase-4 inhibitors (DPP-4i), prospective randomized trials have shown no association between DPP-4i and ischemic events such as myocardial infarction or stroke, but their effects on the risk of heart failure is unclear [13, 14, 15, 16] .
A limited number of bimodal comparison studies have suggested either an increase in cardiovascular events with sulfonylureas or a decrease with metformin or pioglitazone [17, 18] . However, the effects of each of these and other available non-insulin agents individually or with metformin on cardiovascular events still remains uncertain, and future prospective, randomized trials to address these questions are unlikely to be feasible.
The literature on causal inference with observational studies has generally been focused on methodology for binary treatments [19, 20] . Yet, providers and patients frequently must choose among several alternative treatments for type 2 diabetes. The propensity score, which is the probability of receiving treatment conditional on a set of observed covariates, is a common metric used to adjust for observed differences in covariates between two treatment groups in non-randomized observational studies [21] . For more than two treatment groups, the generalized propensity score (GPS) vector represents the probability of receiving any one of the treatments, conditional on the observed covariates [22, 23] .
Inverse probability weighting and doubly robust estimators were proposed as possible solutions to estimate causal effects in observational studies [24, 25, 26] . McCaffrey et al. [24] proposed a method that combines a sandwich estimator with generalized boosted models to obtain point and interval estimates for pairwise average treatment effects. Yoshida et al. [25] developed matching weights to estimate pairwise average treatment effects across the entire population. Li and Li [26] developed balancing weights to estimate pairwise differences in expectations among the subpopulation with the most overlap in covariates across all treatment groups. Possible limitations of weighting methods are that they are limited to specific estimands (e.g., pairwise differences in expectations) and they may suffer from large biases and large standard errors in finite samples because of extreme weights [27] .
Matching algorithms have been proposed as a different approach to estimate causal effects of multiple treatments [27, 28, 29, 30] . Scotina and Gutman [30] observed that matching on the GPS performed well for five treatments or less, but as the number of interventions increases combining matching with a clustering algorithm resulted in better reduction in initial bias. For multiple treatments, statistically valid matching estimators were developed for continuous outcomes and pairwise differences in expectations [29, 31] . Less attention has been given to other outcome types (e.g., binary, time to event, etc.) and other estimands.
To overcome these limitations, we view causal effects as a missing data problem [32, 33] and propose a combination of the Approximate Bayesian Bootstrap algorithm with k-means clustering on the GPS to estimate the causal effects of multiple treatments. The proposed procedure provides statistically valid estimates for different types of outcomes and can be extended to provide interpretable sensitivity analyses. We implemented the proposed procedure to examine the cardiovascular safety of three antihyperglycemic medications to metformin in patients with type 2 diabetes mellitus.
Framework
For units i = 1, . . . , n, let Y obs i , X i , W i , and T iw be the observed outcome, set of P covariates, treatment group identification such that W i ∈ W = {1, . . . , Z}, and an indicator function that is equal to 1 if unit i received treatment w and 0 otherwise. Define n w = n i=1 T iw as the number of units receiving treatment w, where Z w=1 n w = n. A common assumption when estimating causal effects is the stable unit treatment value assumption (SUTVA) [34] , which requires that the potential outcomes for one unit are unaffected by the treatment assignment of others, and that there are no multiple versions of treatment within the same treatment group. Assuming SUTVA, the potential outcomes for unit i and treatment w
With nominal exposure, commonly used estimands of interest with continuous outcomes are the population average treatment effects between treatment groups j and k for all pairs {j, k} ∈ W 2 , over the group of units receiving reference treatment t [27] ,
This can be estimated by using the sample average treatment effect on the treated (ATT),
However, because only one of the potential outcomes is observed and realized for every unit, an important piece of information needed to estimate τ t jk and is the assignment mechanism, P (W = t|X, Y (t)) [27, 32] . To estimate τ t jk , two restrictions are commonly made on the assignment mechanism: (i) P (W = t | X, Y (t)) = P (W = t | X) ≡ r(t, X), and (ii) 0 < r(t, X) < 1 for all t ∈ W [27] . These assumptions are also referred to as strong ignorability [22, 23] .
With binary outcomes, τ t jk and measures the difference
among units receiving treatment t. Other common estimands include the ratio of these probabilities and their odds ratio [35] .
The generalized propensity score (GPS) vector, R(X) = (r(1, X), . . . , r(Z, X)), is an extension of the binary propensity score to multiple exposure levels. Under strong ignorability, comparing units with similar R(X) results in well-defined causal effect estimates [23] . Generally, in observational studies R(X) is unknown and only an estimate of itR(X) = {r(1, X), . . . ,r(Z, X)} is available.
Estimating R(X) is part of the design phase, and several procedures have been described to estimate it [27] . Here, we assume that the R(X) have been estimated to the satisfaction of the researcher without observing any outcome data.
To obtain transitive causal effects estimates and to reduce extrapolation to units that have zero probability of receiving one of the treatments, we restrict the analysis only to units "eligible" to receive all treatments, also referred to as those within the range of common support [27, 36] . For nominal exposure, Lopez and Gutman [27] proposed a rectangular common support region defined byr(w, X) ∈ (r min (w, X),r max (w, X)) for all w ∈ W, wherê r min (w, X) = max{min(r(w, X | W = 1)), . . . , min(r(w, X | W = Z))} r max (w, X) = min{max(r(w, X | W = 1)), . . . , max(r(w, X | W = Z))}.
The ATTs for units within this rectangular common support region are defined as
Matching estimators
Matching has been proposed as a method to estimate causal effects with multiple treatments. The goal of matching is to balance the distribution of covariates across all treatment groups. Similarity in covariates between units in different treatment groups is defined using a distance measure [30] .
Examples of such distance measures include the linear GPS:
|logit(r(w, X i )) − logit(r(w, X j ))|, i = j ∈ {1, . . . , n}, w ∈ {1, . . . , Z}, the Euclidean distance between R(X i ) and R(X j ),
and the Mahalanobis distance between two vectors V i , V j ∈ V,
where Σ is the covariance matrix of V i and V j [27, 29, 30] .
Using a selected distance measure, a common matching algorithm is 1:L nearest neighbor matching, which selects for unit i in the reference treatment t the L individuals in each of the remaining treatment groups with the smallest distance from unit i. When L = 1, each unit in the reference treatment t is paired with its best match from each of the other treatment groups. Increasing L improves precision by reducing the sampling errors, but this improvement may be hindered by increasing bias that arises from the introduction of poorer matches [30, 37] .
A different characteristic of matching algorithms is whether units can be used as matches more than once. Matching "with replacement" can often decrease covariates' bias because nonreference group units that are similar to multiple reference group units can be matched multiple times. However, in some cases matching with replacement may result in only a small number of non-reference units being matched [19] .
Scotina and Gutman [30] found that for five or fewer treatments, matching with replacement on the Mahalanobis distance of the logit GPS vector provided the largest reduction in initial covariate bias between treatment groups. This algorithm was defined as LGPSMnc by [30] . As the number of treatments increases, matching on this distance measure performs worse in terms of reducing initial covariates' bias, because the dimension of the GPS vector increases. With more than five treatments, combining a clustering step with matching on the Mahalanobis distance of the logit GPS resulted in larger reduction in covariates' bias, compared to only matching on the Mahalanobis distance of the logit GPS vector.
Development of inference procedures for causal effect estimation with multiple treatments in matched cohorts has been limited. For matching with replacement, asymptotic point and interval estimators were derived for continuous outcomes and differences in means [29, 31] . However, the performance of these estimators has not been examined for other types of outcomes and estimands. With binary treatment, the bootstrap estimator was found to provide valid inferences when matching without replacement [38] . On the other hand, Abadie and Imbens [39] showed that for matching with replacement the bootstrap method may be statistically invalid in certain situations.
The bootstrap estimator was not examined for multiple treatments.
Weighting estimators
Inverse probability weighting (IPW) is a common approach for estimating causal effects with multiple treatments [24, 25, 26, 40] . Li and Li [26] proposed a general framework for estimating causal effects using generalized propensity score weighting with multiple treatments. Assuming weak unconfoundedness [22] , τ t jk can be estimated aŝ
where r(j, X i ), r(k, X i ), and r(t, X i ) are commonly unknown, and replaced with their corresponding estimatesr(j, X i ),r(k, X i ), andr(t, X i ). To calculate the sampling variance of this estimate, the sandwich estimator, which takes into account the uncertainty in the estimated propensity score, is commonly implemented [24, 26] .
For binary treatment, Gutman and Rubin [33, 41] found that IPW is generally statistically valid, but it is susceptible to extreme weights, which could yield erratic causal estimates. This is exacerbated with a large number of treatments and non-normally distributed covariates [27, 31] .
Imputation procedures
Weighting and matching methods implicitly impute the unobserved potential outcomes. A different approach is to explicitly impute the missing potential outcomes [32, 33, 42] . is independent from Y obs given θ, then samples for P (Y mis t,t | Y obs ) can be obtained by first drawing θ * from its posterior distribution, P (θ|Y obs ) ∝ P (θ)P (Y obs |θ), and then drawing Y mis t,t , conditional on θ * [43, 44].
Hot deck imputation
Hot deck methods were proposed as possible techniques to impute missing data [45] . These methods
replace missing values of one unit (the "recipient") with observed values from another unit (the "donor"). Two common implementations of hot deck imputation methods are the random hot deck and the deterministic hot deck imputation. In the random hot deck imputation, the donor is randomly selected from a set of potential donors, where "potential" is defined according to a distance metric. In the deterministic hot deck imputation, a single donor is identified using a nearest neighbor approach based on a distance metric [45, 46] .
The distance measures that were described in Section 2.1 can be used to create donor pools for hot deck methods. For imputing missing potential outcomes when comparing multiple treatments, one possible procedure to create donor pools is based on k-means clustering [46] . This procedures creates donor pools using k-means clustering on the logit transformation ofR(X), such that patients within each cluster are roughly similar on each component of logit(R(X)) = (logit(r(1, X)), . . . , logit(r(Z, X))), and there is at least one patient from each treatment group in each cluster. Imputation is then performed within each cluster separately. A limitation of this clustering approach is that with a large number of clusters, one or more treatment groups may have a small number or no individuals within a cluster, which would require extrapolation to that cluster [27] . Another limitation of hot deck imputation is that it is not a proper Bayesian imputation method, which results in an underestimation of the sampling variance [45, 47] .
Approximate Bayesian Bootstrap multiple imputation
The Bayesian Bootstrap was proposed as an imputation method, which is based on observed values and reflects the uncertainty in the estimation of population parameters [47] . For a categorical outcome variable, let θ = (θ 1 , . . . , θ L ) represent the probabilities of the outcome taking values d 1 , . . . , d L . Assuming the prior distribution P (θ) ∝ L l=1 θ −1 l , then the posterior distribution is P (θ|Y obs t ) ∝ L l=1 θ q l −1 , where q l is the number of times that the value d l appears in Y obs t . The Bayesian Bootstrap algorithm draws θ * from P (θ|Y obs t ), then Y mis t,t are drawn independently from d 1 , . . . , d l with probability θ * 1 , . . . , θ * l [47] . The Approximate Bayesian Bootstrap (ABB) was proposed as computationally simpler approximation of the Bayesian Bootstrap [47] . For treatments t and t = t, ABB imputes the missing potential outcomes Y mis t,t for treatment group t by: (i) drawing n t components with replacement from Y obs t ; (ii) drawing n t components with replacement from the n t deaws in (i). This double resampling procedure approximates the Bayesian Bootstrap and results in valid statistical inference [48] . Both the Bayesian Bootstrap and the ABB do not adjust for potential covariates. Lavori [49] proposed a procedure that performs the ABB within propensity score subclasses.
We propose a procedure that combines k-means clustering with multiple imputation using ABB to estimate causal effects of multiple treatments. Formally, to estimate τ t jk :
1. Partition patients into Q subclasses based on logit(R(X)) using k-means clustering, and ensure that there is at least one treated unit from each treatment group in each cluster.
2. Within each cluster q ∈ {1, . . . , Q}:
(a) Let O q w be the set of units in subclass q which received treatment w, and let n q w = |O q w | be the cardinality of O q w . For each treatment w = t ∈ W, draw n q w values from O q w with replacement, where each element has 1/n q w probability of being selected. This forms the donor pool,Õ q w , for each treatment w.
(b) For each w, draw n q t values fromÕ q w with replacement. Each of the elements inÕ q w has equal probability of being selected.
3. Repeat steps 2(a) and 2(b) M = 25 times.
This creates M imputed datasets, each containing imputed missing potential outcomes for patients in treatment group t.
Letτ t(m) jk denote the estimated ATT between treatments j and k from imputed dataset m = 1, . . . , M , and letV (m) jk be its estimated sampling variance. The point estimate for τ t jk iŝ
and the standard error is estimated by
While we use M = 25 imputations, the standard error can be estimated using percentiles ofτ t(m) jk when M > 100 [33] .
One limitation of implicit imputation methods such as weighting and matching is that inference is generally limited to specific estimands. Obtaining interval estimates for other estimands is generally complex and relies on asymptotic approximations. An advantage of the proposed ABB procedure is that it can provide valid inference for any estimand, because it explicitly imputes the missing potential outcomes.
Simulation Study

Design
To examine the operating characteristics of the different procedures, we constructed simulation analyses. The first set of factors describes the covariate distributions of Z = 3 treatment groups, which are either known to the investigator, or can be estimated without outcome data. The second set of factors describes the response surfaces, which are unknown to the investigator.
We generated the P = 18 covariates' values for n 1 = 1200, n 2 = 2400, and n 3 = 4800 units receiving treatments 1, 2, and 3, respectively, from multivariate skew-t distributions with 7 degrees of freedom [50] :
, where 1 P is a P × 1 vector of 1s, and b w is a 3 × 1 vector such that the w value is equal to b and the rest are zeros, b ∈ {0, 0.25, 0.50, 0.75, 1}. As the value of b increases there is larger initial bias across the different treatment groups.
We assumed that Y i (w) ∈ {d 1 , . . . , d L }, and we only examined monotone response surfaces.
Binary potential outcomes, Y i (w) ∈ {0, 1}, were simulated from Bernoulli distributions with success
where β X = (2, 4, 6, 1, . . . , 1) is a P × 1 vector that governs the association between X i and Y i (w). When γ = −1 the response surfaces for treatment groups 2 and 3 are mirror images of the response surface in treatment group 1 multiplied by a constant.
We used two link functions for monotone response surfaces: the logistic, and the normal (probit), both of which are symmetric.
, the values were simulated using the proportional odds model,
where α 1 = 1, α 2 = 0.05, α 3 = −0.05, and α 4 = −1.
The simulations were performed as a full factorial design of the factors described in Table 1 .
Each simulation configuration was replicated 200 times. At each replication , = 1, . . . , 200, we estimated each pairwise ATT and the standard error, for each of the procedures. Using these values we recorded at each replication the following measures: 
To summarize the bias, we calculated the mean and standard deviation of |bias (j,k) | across the 200 replications. The median SE(τ t (j,k) ) across the 200 replications was used to summarize the standard errors of each pairwise comparison.
We summarized matching performance using maximum absolute standardized pairwise bias, M ax2SB p , for each pair of treatments and each covariate p,
This metric reflects the largest discrepancy in estimated means between any two treatment groups for covariate p [24, 27, 30] . McCaffrey et al. [24] advocated a cutoff of 0.20 but maintained that larger cutoffs may be appropriate for different applications. We summarized this metric over all covariates for each replication by calculating the maximum bias, M axM ax2SB = max p=1,...,P (M ax2SB p ).
To summarize clustering performance, the SB pjk were calculated within each cluster and weighted across clusters, with weights proportional to the number of units within each cluster.
The following methods were compared: nearest neighbor matching for multiple treatments using the LGPSMnc algorithm from Scotina and Gutman [30] , IPW [24] , and ABB multiple imputation with k-means clustering using Q ∈ {1, 3, 5, 7} clusters.
Results for clustering and matching performance
Covariates' balance across treatment groups for k-means clustering and matching is depicted in 
Results for 95% interval coverage, bias, and standard error
To identify the simulations' factor with the largest influence on the performance of the different estimation methods, we examined the factors' MSE for interval coverage between treatments 1 and 2 and treatments 1 and 3 (as in the works of Lopez and Gutman, Scotina and Gutman, and Cangul et al. [27, 30, 51] ). Across all of the methods that were examined, initial covariates' bias, b, was found to be the most influential factor on coverage rates.
We will begin by describing the simulation results for Y i (w) ∈ {0, 1}. Tables 2 and 3 show the 95% coverage rates, mean absolute bias, and standard errors for the ATT measured as pairwise risk differences with treatment group 1 as the reference across levels of b when the treatment effect is null or non-null, respectively. When there is small initial bias, all of the methods perform well with IPW having the smallest standard errors. However, as the initial bias increases, ABB with Because ABB with k-means clustering is not restricted to a specific estimand, we examined its performance for estimating the log odds ratio and the log risk ratios. Tables 6-9 display the 95% coverage, mean absolute bias and standard errors across the different levels of b. The results are generally similar to the ones observed for risk differences. Specifically, ABB with Q ∈ {5, 7} clusters generally has coverages that are close to nominal. Both methods may result in undercoverage when the initial bias is large.
The results for ordinal outcomes are similar to the ones observed for binary outcomes. Table 10 shows the 95% coverage rates, mean absolute bias, and standard errors for the ATT measured as pairwise risk differences with treatment group 1 as the reference across levels of b when the outcome is ordinal. Each of the examined methods perform well with small initial bias. ABB with either 5 or 7 clusters generally yield the smallest absolute bias and standard errors as the initial bias increases. The CPRD represents complete data from the U.K. National Healthcare System, and previous validation studies have reported on the accuracy of its diagnostic data [52] . Diagnostic information in the CPRD is coded using Read codes, the standard clinical terminology system used in the U.K.
A subset of patients is linked to additional datasets from the Hospital Episode Statistics inpatient data, which include information about National Health Service inpatient visits. To ensure that we have complete hospitalizations records we restricted the analysis only to the subset of patients that can be linked. Primary and additional causes of hospital admissions are coded using ICD-10 codes.
We restrict our analysis to CPRD patients who were new users of antihyperglycemic treatments.
Specifically, to be included in the study patients had (i) received their first ever prescription for (S) (72% of DPP-4i users), or pioglitazone (P) (83% of TZD users), we further restricted the study population to patients who initiated dual-therapy with one of these three agents. The analyses were performed using an intention-to-treat approach, such that patients were assigned to a cohort once they met the criteria, regardless of future changes in treatment regimen not otherwise specified, such as adding a third agent (see Appendix for a summary of cohort selection). were defined if they were diagnosed within two years prior to the index date, and concurrent medication use was defined as at least one filled prescription in the year prior to the index date.
The primary analysis was the average treatment effect among gliclazide add-on users, estimated using three-year pairwise risk differences of major adverse cardiovascular events (MACE) and allcause mortality (ACM). MACE included fatal/non-fatal CVD including myocardial infarction, fatal/non-fatal CHF, and stroke. These outcome events were ascertained using ICD-10 codes for patients linked with Hospital Episode Statistics (see Appendix for ICD-10 codes) and Read codes for the rest [53] . Table 4 lists the covariates, along with a p-value testing the null hypothesis of no dependency between second-line treatment initiation and each covariate. To estimate the GPS model, we used a multinomial logistic regression model that included all of the baseline covariates in Table 4 as explanatory variables. Causal effects were estimated using ABB with k-means clustering on logit(R(X)) with Q ∈ {1, 3, 5, 7} clusters, 1:1:1 nearest neighbor matching on the Mahalanobis distance of the logit GPS vector with replacement [30] , and IPW [24] . Because some of the baseline covariates had missing values, we created 20 multiple complete datasets by applying the fully conditional specification approach in each arm separately using the mice package [54] . We restricted the analysis only to units within the range of common support, E i . IPW and matching were implemented in each imputed dataset and the results were combined using the common multiple imputation rules [55] . When using ABB, imputation was performed in each of the complete datasets and final point and interval estimates were obtained using the common combination rules for twostage imputation [56] .
Of the 15,484 metformin users included in the analysis, 10,487 (68%) had initiated dual-therapy with gliclazide, 3,180 (21%) with sitagliptin and 1,817 (12%) with pioglitazone. The median patient age was between 60 and 61 years for each group. Diabetes duration was less than five years for 82% of the patients and between five and ten years for 18% of the patients. Median time on metformin monotherapy was approximately 2.5-2.6 years for all groups. HbA1c levels were between 8.4-8.7 for each group, reflecting similar blood glucose control. Pioglitazone users had the highest prevalence of hypertension, neuropathy, and retinopathy at initiation.
Results
Covariate balance diagnostics in the form of M ax2SB p in the initial cohort and the cohort after We set metformin plus gliclazide as the reference level. The estimated causal effects in the three-
year risk of MACE or ACM using ABB with k-means clustering, matching, and IPW are depicted in Table 5 . The baseline rates of MACE and ACM when using ABB for each of the three second-line treatment groups is given in Table 11 in the Appendix. Pairwise comparisons between gliclazide and Pairwise comparisons between gliclazide and pioglitazone and sitagliptin and pioglitazone yielded uniformly small and non-statistically significant differences in three-year risk of ACM. Similar trends occur when using the three-year risk ratio with ABB, shown in Table 12 in the Appendix. The interval estimates of all these methods overlapped and included 0.
Sensitivity analysis
All of the proposed methods rely on the strong ignorability assumption which is untestable with observed data. To examine the validity of this assumption with ABB, we propose an interpretable sensitivity analysis.
We examine the sensitivity of the τ G G,S and τ G G,P to an unmeasured covariate by introducing a continuous variable ξ that is independent from the observed covariates. We assume that ξ i is Normally distributed with mean δY obs i +φT i,S +φT i,P and a variance of 1. In this model, φ represents the initial bias in ξ i when comparing gliclazide to sitagliptin or gliclazide to pioglitazone, and exp(δ) represents the odds ratio of Y obs i ∈ {0, 1} given an increase of one unit in ξ i .
To provide intuition to this sensitivity analysis, it is useful to consider two possible scenarios.
The first scenario is when the signs of δ and φ are the same. Under this scenario, the distribution of ξ with Y obs i = 1 among gliclazide users is more similar to the distribution of ξ with Y obs i = 0 among pioglitazone or sitagliptin users. Thus, these units would be more similar when ξ is included in the generalized propensity score estimation, which will yield a larger estimated ATT. In the second scenario, the signs of δ and φ are opposite. As a consequence, the distribution of ξ with Y obs i = 0 among gliclazide users is more similar to the distribution of ξ with Y obs i = 1 among pioglitazone or sitagliptin users. This scenario will yield a smaller estimated ATT when ξ is included in the generalized propensity score estimation.
We estimatedτ G G,S andτ G G,P for MACE using the observed data and ξ. The GPS estimation included ξ as another covariate in the multinomial logistic regression model, and used ABB with k-means clustering that assumed Q = 5. Figure 4 displays the standardized effects,τ G G,S /SE(τ G G,S ) andτ G G,P /SE(τ G G,P ) for MACE, for φ ∈ (−1, 1) and for δ ∈ (−1, 1) . Table 5 , the standardized difference in MACE risks between gliclazide and sitagliptin is close to zero before introducing ξ (e.g. φ = 0 and δ = 0). When incorporating ξ into the estimation procedure, the standardized effects are most sensitive to configurations with |δ| ≥ 0.5 and |φ| ≥ 0.5. The absolute value of the standardized effect was greater than 2 for these configurations.
This implies that in order to find a statistically significant effect, the unobserved covariate should have a standardized initial bias greater than 0.5 or an odds ratio that is greater than exp(0.5).
The standardized difference in MACE risks between gliclazide and pioglitazone is equal to 3.99 before introducing ξ. When incorporating ξ in these comparisons, the standardized effects are
the standardized effect approached 0 for these configurations. None of the observed covariates had initial bias that is greater than 0.3. In addition, an odds ratio of 1.6 is similar to a moderate Cohen's d [57] . Thus, we can conclude that the estimates are relatively robust to the strong ignorability assumption.
Discussion
Many problems in public health involve comparing three or more interventions. This paper proposes an approximate Bayesian bootstrap (ABB) procedure that uses k-means clustering on the generalized propensity score (GPS) to estimate causal effects of multiple nominal treatments. The k-means clustering component ensures that donors have relatively similar covariate values, and the ABB component imputes the unobserved potential outcomes. This procedure can be used with binary or categorical outcomes, and it provides a statistically valid inference procedure for any estimand. We also describe a sensitivity analysis to the strong ignorability assumption. The sensitivity analysis can be implemented within the proposed ABB procedure and it is interpretable using graphical visualization.
Using simulations, we compared the performance of the newly proposed procedures to matching and IPW estimators. For these simulation configurations we observed that ABB with k-means clustering is generally accurate and precise when using 5 or 7 clusters compared to weighting and matching methods.
The simulation study used Z = 3 treatment groups and the logit GPS vector as a distance measure for k-means clustering and matching. Scotina and Gutman [30] found that this distance measure can perform poorly in terms of reducing covariate bias between treatment groups, when used in matching algorithms with Z > 5. An area for future work would be to identify the operating characteristics for ABB multiple imputation with k-means clustering when there is a large number of treatments. ABB with k-means clustering only imputes the missing potential outcomes based on the GPS. A potential extension would be to impute missing potential outcomes based on a model that includes the generalized propensity score and covariates that predict the outcome. This type of modeling was shown to yield more precise and accurate estimates with two treatments [33, 58] .
For the nearly 20 million people affected with type 2 diabetes in the United States, acute myocardial infarction is a very serious and potentially fatal complication of the disease, the choices of treatments are highly complex [59] , and the effects of various antihyperglycemic treatments on macrovascular events is uncertain [60, 61] . The analysis presented here is a novel approach to comparing the risks of major adverse cardiovascular events (MACE) and all-cause mortality (ACM) of multiple second-line antidiabetic medications using observational data [9, 53, 62] . We show that, among patients who initiate second-line treatment after metformin monotherapy, there is a significantly higher three-year risk of MACE for users of gliclazide and sitagliptin compared to users of pioglitazone. Further, there is a significantly higher three-year risk of ACM for gliclazide second-line users compared to sitagliptin second-line users. It will be of interest to explore the use of this methodology to investigate the effects of these antihyperglycemic agents and other members of the sulfonylurea and DPP-4i drug classes in other large clinical databases. As more real-world clinical data with new antihyperglycemic agents that have shown evidence for cardiovascular benefit, such as members of the sodium glucose co-transporter 2 inhibitor class [63, 64] , become available, it will be of interest to determine whether the observations from prospective, randomized clinical trials with these agents are confirmed.
In conclusion, we provide a general method for estimating causal effects using the generalized propensity score that can be applied to binary or categorical outcomes and any estimand of interest.
Based on our simulations, ABB with k-means clustering using K ∈ {5, 7} clusters generally yields valid, accurate, and precise estimates of average treatment effects. 
